EGFR mutations are more prevalent in Asia than other geographical regions and have been reported in up to 49.1% of Asian NSCLC patients with advanced stage (Benbrahim et al. 2018; Melosky et al. 2022). Here, EGFR is linked to non-small cell lung carcinoma.